Literature DB >> 8381223

p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells.

A Puisieux1, F Ponchel, M Ozturk.   

Abstract

Mutations of the p53 detected in human hepatocellular carcinomas suggest that its inactivation is a critical step in hepatocellular carcinogenesis. In order to test whether the expression of p53 is compatible with the transformed phenotype of hepatoma cells, we transfected Hep 3B cell line with p53 expression vectors. This cell line, which contains integrated hepatitis B virus sequences, is a good model to study whether the wild-type p53 can function as a tumour suppressor gene in virus-related hepatocellular carcinoma. Wild-type and mutant p53 (Ala143)-expression vectors containing a neoR gene were used. The number of antibiotic-resistant colonies was six times lower after transfection with wild-type p53 vector as compared to the mutant vector. As measured by a specific radioimmunoassay, six of eight (75%) colonies randomly selected after mutant p53 transfections expressed the transfected mutant p53 protein. In contrast, out of eight colonies from wild-type p53-transfections, none expressed detectable p53 protein. The absence of p53 protein was due to the selective deletion of transfected wild-type p53 cDNA sequences. These studies demonstrate that the growth of hepatocellular carcinoma cells is not compatible with the expression of wild-type p53. Therefore, p53 should be considered as a tumour suppressor gene in hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381223

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Disease progression and liver cancer in the ferroportin disease.

Authors:  Elena Corradini; Francesca Ferrara; Teresa Pollicino; Alberto Vegetti; Gian Luca Abbati; Luisa Losi; Giovanni Raimondo; Antonello Pietrangelo
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

Review 2.  Tumor suppressor genes in molecular medicine.

Authors:  F Hoppe-Seyler; K Butz
Journal:  Clin Investig       Date:  1994-08

3.  p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus.

Authors:  A Puisieux; J Ji; C Guillot; Y Legros; T Soussi; K Isselbacher; M Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

4.  Molecular characterization of p53 mutations in primary and secondary liver tumors: diagnostic and therapeutic perspectives.

Authors:  Apollonia Tullo; Elisabetta Sbisà
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

5.  Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms.

Authors:  A Puisieux; J Ji; M Ozturk
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

6.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Ju-Yann Wu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

7.  Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.

Authors:  K Ory; Y Legros; C Auguin; T Soussi
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.